New Scientific Publication Explains How LDB B-30892 Inhibits the Cytotoxic Effects of Clostridium difficile

LacPro Industries LLC, a probiotic-based biotherapeutics company, announces a publication in the peer-reviewed scientific journal, Gut Pathogens, entitled, "Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells.” In this scientific publication, the research team explains the published in vitro research demonstrating the beneficial effect of LacPro's proprietary probiotic strain. - April 28, 2009

LacPro Industries, LLC Named Techpoint Mira Award Finalist

Fort Wayne-based LacPro, a biotherapeutic company developing a product for Clostridium difficile Infection, has been named a finalist for Innovation of the Year. - April 22, 2009

Press Releases 1 - 2 of 2